Initiation Of Phase III Program Using Emisphere's Eligen(R) Technology For Oral Salmon Calcitonin

Wed, 28 Feb 2007 02:00 PM EST

... Emisphere Technologies, Inc. ("Emisphere") (Nasdaq: EMIS) announced today that Novartis Pharma AG and its development partner Nordic Bioscience have notified Emisphere of the initiation of a Phase III clinical trial for the treatment of osteoporosis with an oral form of salmon calcitonin (referred to as SMC021), a new drug candidate, using Emisphere's eligen(R) delivery technology. [click link for full article] ...